Kiora Pharmaceuticals (FRA:7EY) 9-Day RSI: N/A (As of Jul. 12, 2026)


FRA:7EY Kiora Pharmaceuticals Inc FRA:7EY
34 GF Score
Price €0.42
! 3 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2026-07-12), Kiora Pharmaceuticals's 9-Day RSI is N/A.

The industry rank for Kiora Pharmaceuticals's 9-Day RSI or its related term are showing as below:

FRA:7EY's 9-Day RSI is not ranked *
in the Biotechnology industry.
Industry Median: 50.12
* Ranked among companies with meaningful 9-Day RSI only.

Kiora Pharmaceuticals  (FRA:7EY) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Kiora Pharmaceuticals 9-Day RSI Related Terms


FRA:7EY vs PHIO, PBM, OSRH: 9-Day RSI Comparison

For the Biotechnology subindustry, Kiora Pharmaceuticals's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiora Pharmaceuticals 9-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's 9-Day RSI falls into.


FRA:7EY
34GF Score
Kiora Pharmaceuticals Inc FRA:7EY
9-Day RSI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiora Pharmaceuticals  (FRA:7EY) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kiora Pharmaceuticals Business Description

Other Exchanges KPRX:USA
Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
34GF Score

Get the complete analysis for FRA:7EY

9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.42
Price